Guido Neels Biography and Net Worth

Director of Elutia

In addition to his board responsibilities at Elutia, Guido Neels currently serves on the Board of Directors of EW growth equity portfolio companies Enercon Technologies and Bioventus.

Mr. Neels previously served as Chief Operating Officer of Guidant Corporation, where he was responsible for the operations of Guidant’s four operating units, Cardiac Rhythm Management, Vascular Intervention, Cardiac Surgery, and Endovascular Solutions. Prior to that he was responsible for Guidant’s sales operations, corporate communications, corporate marketing, investor relations and government relations. He also served as Vice President of Global Marketing for Vascular Intervention and as Managing Director for German and Central European operations. Prior to joining Guidant, Mr. Neels held general management, sales and marketing positions at Eli Lilly & Company in the U.S. and Europe.

Mr. Neels holds a Business Engineering degree from the University of Leuven in Belgium and a Master of Business Administration degree from Stanford University.

What is Guido J. Neels' net worth?: The estimated net worth of Guido J. Neels is at least $96.19 thousand as of January 30th, 2026. Mr. Neels owns 118,750 shares of Elutia stock worth more than $96,188 as of September 29th. This net worth evaluation does not reflect any other assets that Mr. Neels may own. Learn More about Guido J. Neels' net worth.
How do I contact Guido J. Neels?: The corporate mailing address for Mr. Neels and other Elutia executives is 12510 Prosperity Drive, Suite 370, Silver Spring, MD, 20904. Elutia can also be reached via phone at (240) 247-1143 and via email at [email protected]. Learn More on Guido J. Neels' contact information.
Has Guido J. Neels been buying or selling shares of Elutia?: Guido J. Neels has not been actively trading shares of Elutia in the last ninety days. Most recently, on Friday, January 30th, Guido J. Neels bought 20,000 shares of Elutia stock. The stock was acquired at an average cost of $1.04 per share, with a total value of $20,800.00. Following the completion of the transaction, the director now directly owns 118,750 shares of the company's stock, valued at $123,500. Learn More on Guido J. Neels' trading history.
Who are Elutia's active insiders?: Elutia's insider roster includes David Colpman (Director), Thomas Englese (Insider), Matthew Ferguson (CFO), Ronald Lloyd (CEO), Brigid Makes (Director), C. Randal Mills (President & CEO), Guido Neels (Director), and Kevin Rakin (Director). Learn More on Elutia's active insiders.
Are insiders buying or selling shares of Elutia?: In the last year, Elutia insiders bought shares 13 times. They purchased a total of 299,500 shares worth more than $220,810.00. The most recent insider tranaction occured on January, 30th when Director Guido J. Neels bought 20,000 shares worth more than $20,800.00. Insiders at Elutia own 17.8% of the company. Learn More about insider trades at Elutia.
Information on this page was last updated on 1/30/2026.

Guido J. Neels Insider Trading History at Elutia

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/30/2026	Buy	20,000	$1.04	$20,800.00	118,750
1/28/2026	Buy	15,000	$1.06	$15,900.00	83,750

Guido J. Neels Buying and Selling Activity at Elutia

Elutia Company Overview

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Today's Range

Now: $0.81

$0.81

$0.83

50 Day Range

MA: $0.87

$0.79

$1.01

2 Week Range

Now: $0.81

$0.50

$1.39

Volume

5,640 shs

Average Volume

31,025 shs

Market Capitalization

$35.87 million

P/E Ratio

0.85

Dividend Yield

N/A

Beta

0.88